6H-furo[2,3-E]indole Compounds for Hepatitis C Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis C virus (HCV) infection, particularly those involving HCV NS5B inhibitors, face challenges such as hepatic toxicity and limited efficacy, necessitating the development of novel compounds with improved mechanism of action, binding affinity, target selectivity, solubility, safety profiles, and bioavailability.
Innovation Solution
Development of compounds of Formula I, including pharmaceutically acceptable salts, which demonstrate activity against HCV NS5B, and their use in pharmaceutical compositions and methods for treating HCV infection, either alone or in combination with other anti-HCV compounds like interferon or ribavirin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current HCV NS5B inhibitors are used for treatment, then viral replication is inhibited, but hepatic toxicity occurs and efficacy is limited
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of HCV NS5B inhibitors through systematic variation of substituents at positions R1-R11 in Formula I. These structural parameter changes aim to optimize the balance between antiviral efficacy and hepatic toxicity, producing compounds with improved therapeutic indices compared to existing inhibitors.
Solution Approach 2:
The patent employs local quality by introducing specific substituent patterns at different positions of the core molecular structure. By selectively modifying local regions of the molecule (different R groups), the patent optimizes specific properties such as binding affinity to NS5B while minimizing off-target effects that cause hepatic toxicity.
2Reliability
If existing HCV therapies are administered, then some viral load reduction is achieved, but sustained efficacy is limited in a substantial fraction of patients
Solution Approach 1:
The patent applies preliminary action by designing compounds with optimized pharmacokinetic properties that maintain sustained drug levels in the body. The molecular structures in Formula I are configured to achieve prolonged half-life and sustained NS5B inhibition, ensuring continuous viral suppression without requiring frequent dosing adjustments.
3Reliability
If novel compounds with improved mechanism of action are developed, then treatment efficacy may be enhanced, but compound complexity and development difficulty increase
Solution Approach 1:
The patent applies segmentation by dividing the complex molecular structure into distinct modular components (core structure with variable R1-R11 substituents). This modular approach allows systematic optimization of each region independently while maintaining overall compound manageability and facilitating structure-activity relationship studies.
Data Source
AI summary
Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.